The FDA has approved semaglutide for the treatment of type 2 diabetes under the brand names Ozempic and Rybelsus
Semaglutide The active ingredient in Wegovy and Ozempic The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group, as compared with -2.4% with placebo. STEP 1, Wilding JPH et al., NEJM 2021;384:989-1002 Tirzepatide The active ingredient in Mounjaro and Zepbound At 72 weeks, the mean percentage change in weight was -20.9% with 15 mg of tirzepatide, as compared with -3.1% with placebo. SURMOUNT-1, Jastreboff AM et al., NEJM 2022;387:205-216 These figures are trial averages for the branded formulations
For the appropriate patient, the barrier is most often the monthly copays and costs without insurance coverage
Q: If BPC-157 is genuinely promising, why hasn't a proper trial been done
Insurance coverage information is subject to change always verify with your specific plan
Prioritise Protein for Sustained Energy (The Non-Negotiable) When your calorie intake is low, protein is your single most important macronutrient